Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Depreciation & Amortization (CF) (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $36.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 28.38% to $36.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.7 million through Dec 2025, down 17.51% year-over-year, with the annual reading at $141.7 million for FY2025, 17.51% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $36.0 million at BeOne Medicines, down from $37.3 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $71.3 million in Q3 2024, with the low at $9.6 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $25.7 million, with a median of $21.9 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 231.44% in 2024, then tumbled 47.7% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $13.1 million in 2021, then soared by 37.31% to $18.0 million in 2022, then skyrocketed by 32.21% to $23.8 million in 2023, then skyrocketed by 110.95% to $50.2 million in 2024, then dropped by 28.38% to $36.0 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $36.0 million, $37.3 million, and $35.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.